PSIL - ETF AI Analysis
Top Page
AdvisorShares Psychedelics ETF (PSIL)
Rating:47Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past few months, indicating positive momentum in its niche market.
Leading Holdings Showing Strength
Several of the largest positions, including Atai Beckley, Definium Therapeutics, COMPASS Pathways, NRX Pharmaceuticals, GH Research, Neurocrine, and Alto Neuroscience, have delivered strong year-to-date performance that supports the fund’s returns.
Focused Exposure to Psychedelic Health Care
The heavy allocation to health care companies involved in psychedelics provides targeted exposure to a specialized growth theme for investors who want to bet on this segment.
Negative Factors
High Expense Ratio
The ETF charges relatively high annual fees, which can eat into investor returns over time compared with lower-cost funds.
Concentrated Holdings and Sector Risk
A small number of health care stocks make up a large portion of the portfolio, increasing the impact that problems at any one company or in the sector could have on the fund.
Limited Geographic Diversification
The fund is heavily invested in U.S. and Canadian companies, offering little exposure to other regions and making it more sensitive to North American market and regulatory conditions.
PSIL vs. SPDR S&P 500 ETF (SPY)
AUM49.43M
RegionGlobal
Expense Ratio1.00%
Beta0.95
IssuerAdvisorShares
Inception DateSep 15, 2021
Dividend Yield8%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume41,494
30 Day Avg. Volume41,174
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
55.37Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering28
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSIL Summary
PSIL is the AdvisorShares Psychedelics ETF, a fund that invests in health care companies working with psychedelic drugs for mental health treatment. It doesn’t track a traditional index, but instead focuses on a theme: pharma, biotech, and life sciences firms developing new therapies for depression, anxiety, PTSD, and addiction. Top holdings include names like COMPASS Pathways and Cybin, which are known for their work in psychedelic medicine. Investors might consider PSIL for growth potential in an emerging area of health care, but should know it is concentrated in a small, risky niche and its price can move sharply up or down.
How much will it cost me?The AdvisorShares Psychedelics ETF (PSIL) has an expense ratio of 0.99%, meaning you’ll pay $9.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise involved in selecting investments.
What would affect this ETF?The AdvisorShares Psychedelics ETF (PSIL) could benefit from increasing acceptance of psychedelics in mainstream medicine and growing investment in mental health treatments, particularly for conditions like depression and PTSD. However, regulatory hurdles, slow drug approval processes, and potential shifts in public perception or government policies could negatively impact the sector’s growth. Global exposure and reliance on innovative but early-stage companies may add both opportunities and risks for investors.
PSIL Top 10 Holdings
PSIL is a tightly focused bet on psychedelic and mental-health biotech, with a global roster of mostly early-stage drug developers. Atai and Definium Therapeutics are the main engines, with rising momentum over the past few months helping drive the fund’s performance. Compass Pathways and GH Research have been more mixed, showing promise but also reminding investors how bumpy the clinical-trial road can be. Relmada is clearly lagging, acting as a bit of a weight. A smaller stake in established player AbbVie adds a steadier, big-pharma anchor to this otherwise speculative mix.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Atai Beckley N.V. | 14.15% | $6.88M | $2.66B | 72.18% | 47 Neutral | |
| Definium Therapeutics | 12.05% | $5.86M | $5.91B | 415.64% | 40 Neutral | |
| COMPASS Pathways | 9.83% | $4.78M | $1.56B | 161.52% | 47 Neutral | |
| Cybin | 5.47% | $2.66M | ― | ― | 37 Underperform | |
| Relmada Therapeutics | 5.32% | $2.59M | $561.16M | 800.00% | 41 Neutral | |
| GH Research | 4.82% | $2.34M | $1.95B | 104.29% | 45 Neutral | |
| NRX Pharmaceuticals | 4.74% | $2.30M | $130.86M | 21.62% | 45 Neutral | |
| Neurocrine | 4.66% | $2.27M | $18.65B | 29.39% | 80 Outperform | |
| Alto Neuroscience, Inc. | 4.55% | $2.21M | $1.11B | 787.54% | 42 Neutral | |
| Bright Minds Biosciences | 4.44% | $2.16M | C$1.02B | 130.74% | 48 Neutral |
PSIL Technical Analysis
Positive
―
Price Trends
22.14
Positive
20.28
Positive
18.74
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSIL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 23.69, equal to the 50-day MA of 22.14, and equal to the 200-day MA of 18.74, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSIL.
PSIL Peer Comparison
Comparison Results
Performance Comparison
PSIL
AdvisorShares Psychedelics ETF
23.50
8.20
53.59%
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents